These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 26108379)

  • 1. Financial Analysis of CYP2C19 Genotyping in Patients Receiving Dual Antiplatelet Therapy Following Acute Coronary Syndrome and Percutaneous Coronary Intervention.
    Johnson SG; Gruntowicz D; Chua T; Morlock RJ
    J Manag Care Spec Pharm; 2015 Jul; 21(7):552-7. PubMed ID: 26108379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome.
    Kazi DS; Garber AM; Shah RU; Dudley RA; Mell MW; Rhee C; Moshkevich S; Boothroyd DB; Owens DK; Hlatky MA
    Ann Intern Med; 2014 Feb; 160(4):221-32. PubMed ID: 24727840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CYP2C19 LOF and GOF-Guided Antiplatelet Therapy in Patients with Acute Coronary Syndrome: A Cost-Effectiveness Analysis.
    Jiang M; You JH
    Cardiovasc Drugs Ther; 2017 Feb; 31(1):39-49. PubMed ID: 27924429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of cytochrome P450 2C19 polymorphism on adverse cardiovascular events after drug-eluting stent implantation in a large Hakka population with acute coronary syndrome receiving clopidogrel in southern China.
    Zhong Z; Hou J; Zhang Q; Li B; Li C; Liu Z; Yang M; Zhong W; He X; Wu H; Zhong M; Zhao P
    Eur J Clin Pharmacol; 2018 Apr; 74(4):423-431. PubMed ID: 29243114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic Evaluations of CYP2C19 Genotype-Guided Antiplatelet Therapy Compared to the Universal Use of Antiplatelets in Patients With Acute Coronary Syndrome: A Systematic Review.
    AlMukdad S; Elewa H; Al-Badriyeh D
    J Cardiovasc Pharmacol Ther; 2020 May; 25(3):201-211. PubMed ID: 32027168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CYP2C19 genotype plus platelet reactivity-guided antiplatelet therapy in acute coronary syndrome patients: a decision analysis.
    Jiang M; You JH
    Pharmacogenet Genomics; 2015 Dec; 25(12):609-17. PubMed ID: 26398625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic testing in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a cost-effectiveness analysis.
    Lala A; Berger JS; Sharma G; Hochman JS; Scott Braithwaite R; Ladapo JA
    J Thromb Haemost; 2013 Jan; 11(1):81-91. PubMed ID: 23137413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of major adverse cardiovascular events of
    Biswas M; Kali MSK; Biswas TK; Ibrahim B
    Platelets; 2021 Jul; 32(5):591-600. PubMed ID: 32664772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contemporary Trends in Oral Antiplatelet Agent Use in Patients Treated with Percutaneous Coronary Intervention for Acute Coronary Syndrome.
    Kim K; Lee TA; Touchette DR; DiDomenico RJ; Ardati AK; Walton SM
    J Manag Care Spec Pharm; 2017 Jan; 23(1):57-63. PubMed ID: 28025925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual Antiplatelet Therapy Guided by CYP2C19 Polymorphisms after Implantation of Second-Generation Drug-Eluting Stents for Management of Acute Coronary Syndrome.
    Ozawa T; Suda M; Ikegami R; Takano T; Wakasugi T; Yanagawa T; Tanaka K; Ozaki K; Hirono S; Minamino T
    Int Heart J; 2018 Jan; 59(1):21-26. PubMed ID: 29279531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A study on the impact of CYP2C19 genotype and platelet reactivity assay on patients undergoing PCI.
    Rath PC; Chidambaram S; Rath P; Dikshit B; Naik S; Sahoo PK; Das B; Mahalingam M; Khandrika L; Jain J
    Indian Heart J; 2015; 67(2):114-21. PubMed ID: 26071289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cost effectiveness of genetic testing for CYP2C19 variants to guide thienopyridine treatment in patients with acute coronary syndromes: a New Zealand evaluation.
    Panattoni L; Brown PM; Te Ao B; Webster M; Gladding P
    Pharmacoeconomics; 2012 Nov; 30(11):1067-84. PubMed ID: 22974536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequency and clinical outcomes of CYP2C19 genotype-guided escalation and de-escalation of antiplatelet therapy in a real-world clinical setting.
    Martin J; Williams AK; Klein MD; Sriramoju VB; Madan S; Rossi JS; Clarke M; Cicci JD; Cavallari LH; Weck KE; Stouffer GA; Lee CR
    Genet Med; 2020 Jan; 22(1):160-169. PubMed ID: 31316169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of CYP2C19 Metabolizer Status on Patients With ACS Treated With Prasugrel Versus Clopidogrel.
    Doll JA; Neely ML; Roe MT; Armstrong PW; White HD; Prabhakaran D; Winters KJ; Duvvuru S; Sundseth SS; Jakubowski JA; Gurbel PA; Bhatt DL; Ohman EM; Fox KAA;
    J Am Coll Cardiol; 2016 Mar; 67(8):936-947. PubMed ID: 26916483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bleeding risk in patients prescribed dual antiplatelet therapy and triple therapy after coronary interventions: the ADAPTT retrospective population-based cohort studies.
    Harris J; Pouwels KB; Johnson T; Sterne J; Pithara C; Mahadevan K; Reeves B; Benedetto U; Loke Y; Lasserson D; Doble B; Hopewell-Kelly N; Redwood S; Wordsworth S; Mumford A; Rogers C; Pufulete M
    Health Technol Assess; 2023 May; 27(8):1-257. PubMed ID: 37435838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contemporary antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention: 1-year outcomes from the GReek AntiPlatElet (GRAPE) Registry.
    Alexopoulos D; Xanthopoulou I; Deftereos S; Hamilos M; Sitafidis G; Kanakakis I; Pentara I; Vavouranakis M; Davlouros P; Hahalis G; Goudevenos J
    J Thromb Haemost; 2016 Jun; 14(6):1146-54. PubMed ID: 26990959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of 6-Month Costs Between Oral Antiplatelet Agents Following Acute Coronary Syndrome.
    Kim K; Lee TA; Touchette DR; DiDomenico RJ; Ardati AK; Walton SM
    J Manag Care Spec Pharm; 2018 Aug; 24(8):800-812. PubMed ID: 30058986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Evaluation of the Cost-effectiveness of Comprehensive MTM Integrated with Point-of-Care Phenotypic and Genetic Testing for U.S. Elderly Patients After Percutaneous Coronary Intervention.
    Okere AN; Ezendu K; Berthe A; Diaby V
    J Manag Care Spec Pharm; 2018 Feb; 24(2):142-152. PubMed ID: 29384027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of cytochrome P450 2C19 genotype screening for selection of antiplatelet therapy with clopidogrel or prasugrel.
    Reese ES; Daniel Mullins C; Beitelshees AL; Onukwugha E
    Pharmacotherapy; 2012 Apr; 32(4):323-32. PubMed ID: 22461122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review of pharmacoeconomic evaluation of genotype-guided antiplatelet therapy.
    Jiang M; You JH
    Expert Opin Pharmacother; 2015 Apr; 16(5):771-9. PubMed ID: 25660101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.